NICE Publish Determination on Ustekinumab for Psoriatic Arthritis…
12th March 2015
The Final Appraisal Determination was published on Thursday 12th March
Photo Shoot Opportunity for Under 21s…
9th March 2015
Young people who have been affected by psoriasis or psoriatic arthritis needed for photo shoot project.
People with Psoriatic Arthritis Needed for PhD Study…
13th February 2015
Online survey looking at the life impact of painful conditions
Local Support Group Details and Meetings for 2015…
11th February 2015
Details of meeting times and dates for our local support groups in 2015.
Article on psoriasis published in British Journal of Dermatology…
13th January 2015
An article comparing long-term drug survival and safety of biologics in patients with psoriasis has been published in the British Journal of Dermatology (BJD).
Psoriasis Association Information Certified as Good Quality…
12th January 2015
We have been recertified under the Information Standard - an accredition held since 2011.
NICE Publish Determination on Ustekinumab for Psoriatic Arthritis
On 12th March 2015, the National Institute for Health and Care Excellence (NICE) published their Final Appraisal Determination for Ustekinumab for treating active psoriatic arthritis. The guidance is as follows:
Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
· Treatment with tumour necrosis factor (TNF) alpha inhibitors [other biologic treatments already approved for psoriatic arthritis, including etanercept, infliximab, adalimumab and golimumab] is contraindicated but would otherwise be consideredor
· The person has had treatment with 1 or more TNF-alpha inhibitors.
Ustekinumab treatment should be stopped if the person’s psoriatic arthritis has not shown adequate response at 24 weeks. As recommended in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis, people whose psoriasis has an adequate response but whose psoriatic arthritis response does not justify continuing treatment should be assessed by a dermatologist to determine whether continuing treatment is appropriate on the basis of skin response.
A Final Appraisal Determination, which has been published for ustekinumab, is the last step in the review process, and is used as a basis for NICE’s final guidance to the NHS, providing no appeals are made by those who consulted during the process. The final guidance for ustekinumab in psoriatic arthritis is expected to be published in May 2015.
You can read the full Final Appraisal Determination here.